A pilot trials of ZD1839 (‘IRESSA’), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with docetaxel and estramustine in patients with hormone-refractory prostate cancer (HRPC). - Trump,D.; Wilding,G.; Small,E.J.; Soulie,P. (J Urol, 2003)